Fredrik Schjesvold, leader of the "Oslo Myeloma Center" research group at the Department of Haematology at Oslo University Hospital, has recently been interviewed by the national broadcasting corporation NRK for the the popular radio programme "Ekko", under the column "Meet a researcher". Schjesvold has also been interviewed for an international multiple myeloma podcast. Furthermore, a video presenting the Oslo Myeloma Center has been produced.
From the NRK radio programme "Ekko", broadcasted April 2018:
"Møt en forsker: Fredrik Schjesvold".
Multiple myeloma podcast: interview with Fredrik Schjesvold (in English, 25 minutes) (click on link to open mp3 file)
Click here to listen directly:
This podcast is exploring the scientific myeloma landscape in the Nordics. In this episode, Dr. Fredrik Schjesvold talks about the current and future perspectives for clinical studies and treatments – and the infrastructure he is part of establishing with Oslo Myeloma Center.
This podcast is part of a series of podcasts within hematology developed and sponsored by Janssen Nordics. www.janssen.com/norway.
Video presentation of Oslo Myeloma Center:
This film shows the breadth of features at Oslo Myeloma Center including:
- A large clinical research activity. (2017: 84 enrolled patients in 11 clinical studies, from phase 1 to phase 3; academic and industry studies). Biggest center in the Nordics, and biggest center in the Nordic Myeloma Study Group. Weekly group meetings, and twice weekly tumor boards. 5-days-a-week study outpatient clinic.
- Our first phase-1-study is now ongoing, and we’re the biggest center. Jan 22nd a patient of ours received the triplet treatment, as the first patient in the world. He might be interviewed.
- Strong collaboration with the translational group KG Jebsen for B cell malignancies (Newly founded), pathophysiology, immunotherapy and drug sensitivity center.
- Large transplant center: 124 autologous transplants in 2017.
- In our hospital we have high-tech facilities for cytogenetics, flowcytometrics, pathology, and PET-CT.
- We have the largest cell laboratory in public health care in Europe, and have CAR-T-cell-experience from two previous studies. We have an amyloidosis group with regular tumor boards, and who have developed a lasermicrodissection-mass spectrometry program.
More news articles (in Norwegian):
From Inven2, 20.04.2018:
Bringer banebrytende behandling for benmargskreft til Norge
From Dagens medisin, 01.02.2018:
Har inkludert 100 pasienter i studier
From VG, 21.08.2017:
Nytt medikament mot benmargskreft godkjent i Norge – etter nesten to år i kø
From Aftenposten, 20.06.2017:
Kreftpasient måtte google seg frem til norsk studie som kan gi ham ekstra levetid